Kodiak Sciences announces treatment of first patients in Phase3 Tarcocimab study

The company states: “Kodiak Sciences announced that the first patients with diabetic retinopathy have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in greater than or equal to 2-step improvement in DRSS (treatment) and 89% decreased risk of developing sight-threatening complications. Consistent with Kodiak’s operational track record of running six pivotal studies in parallel for the tarcocimab program, GLOW2 is on an accelerating trajectory of site activations, new patient screenings and randomizations with the goal to complete enrollment before the end of this year.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue